Coverage
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
Filings
| Filing | Date |
|---|---|
| Information on the AGM of Orion Corporat | 23 Mar 2004 |
| Erkki Etola elected Vice Chairman of Ori | 23 Mar 2004 |
| Orion Group 2003 Financial Statements | 13 Feb 2004 |
| PROPOSALS BY THE BOARD OF DIRECTORS TO T | 13 Feb 2004 |
| 16,800 Orion A-shares converted into B-s | 12 Feb 2004 |
| 35,000 Orion A-shares converted into B-s | 6 Feb 2004 |
| Orion distributes an additional dividend | 11 Dec 2003 |
| Risto Kanerva appointed new President of | 8 Dec 2003 |
| 110,000 Orion A-shares converted into B- | 2 Dec 2003 |
| Additional dividend of EUR 1.50 proposed | 20 Nov 2003 |
| Orion Group Interim Report 1-9/2003 | 5 Nov 2003 |
| EU approval granted for Stalevo, Orion's | 23 Oct 2003 |